Payment overview · 2025
General Payments
$6,017.45
262 reported records · 34 companies
Healthcare provider profile · identity verified
Yelitza Ruiz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · BAYAMON, PR · NPI 1952412918
Verified facts
What the public records show
CMS Open Payments records show Yelitza Ruiz, M.D. received $6,017.45 in general payments during 2025 across 262 reported records.
AstraZeneca Pharmaceuticals LP accounted for 11.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 86 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ibrance, Imbruvica, Lynparza, Tagrisso, Verzenio, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Imbruvica by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 9531 records involving 5030 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lynparza by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Tagrisso by this doctor in 2024.
Eli Lilly Export S.A. Puerto Rico Branch reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 301 records involving 104 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Verzenio by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 10903 records involving 6595 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lynparza by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 367 records involving 97 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ibrance by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 328 records involving 103 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xtandi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $695.50 | 11.6% | 31 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $575.13 | 9.6% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $543.93 | 9.0% | 20 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $399.69 | 6.6% | 20 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $369.67 | 6.1% | 19 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $340.55 | 5.7% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $328.41 | 5.5% | 15 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $309.66 | 5.2% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $285.49 | 4.7% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $230.27 | 3.8% | 10 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $222.95 | 3.7% | 5 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $159.80 | 2.7% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $144.66 | 2.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $141.51 | 2.4% | 5 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $130.71 | 2.2% | 6 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $122.72 | 2.0% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $106.19 | 1.8% | 4 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $98.43 | 1.6% | 5 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $98.12 | 1.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.70 | 1.5% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $84.73 | 1.4% | 4 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $80.19 | 1.3% | 4 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $65.36 | 1.1% | 3 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $64.19 | 1.1% | 3 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $57.32 | 0.9% | 3 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $47.17 | 0.8% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $44.07 | 0.7% | 2 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $44.07 | 0.7% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $36.42 | 0.6% | 2 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $24.53 | 0.4% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.00 | 0.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.95 | 0.3% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.42 | 0.3% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.94 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,939.46 | 261 |
| Education | $77.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $328.41 | 15 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $309.66 | 14 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $289.63 | 15 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Pharmaceuticals, Inc | $280.84 | 12 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $278.17 | 8 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $256.22 | 11 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $237.22 | 8 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $222.95 | 5 | 2025 |
Source payment records
|
|||||
| KYPROLIS Normalized: kyprolis |
Drug | Amgen Inc. | $206.59 | 11 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Pharmaceuticals, Inc | $201.09 | 9 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $159.80 | 7 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $154.75 | 7 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $149.77 | 7 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $145.18 | 6 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $144.16 | 6 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Pharmaceuticals, Inc | $136.10 | 6 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $134.80 | 6 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $131.22 | 6 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Puerto Rico Inc. | $130.71 | 6 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PBG PUERTO RICO LLC | $124.86 | 7 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $122.72 | 5 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $122.72 | 5 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $119.73 | 4 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Pharmaceuticals, Inc | $112.15 | 5 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Puerto Rico Inc. | $108.69 | 5 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $106.19 | 4 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PBG PUERTO RICO LLC | $103.28 | 5 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PBG PUERTO RICO LLC | $103.28 | 5 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $98.43 | 5 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $98.12 | 4 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $90.70 | 4 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $89.72 | 4 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $88.14 | 4 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $85.06 | 4 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $80.24 | 4 | 2025 |
Source payment records
|
|||||
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $80.19 | 4 | 2025 |
Source payment records
|
|||||
| IMDELLTRA (AMG757) Normalized: imdelltra amg757 |
Biological | Amgen Inc. | $78.90 | 4 | 2025 |
Source payment records
|
|||||
| LUMAKRAS Normalized: lumakras |
Drug | Amgen Inc. | $78.90 | 4 | 2025 |
Source payment records
|
|||||
| XGEVA Normalized: xgeva |
Biological | Amgen Inc. | $78.90 | 4 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $73.08 | 3 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $70.75 | 3 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $70.75 | 3 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $67.35 | 3 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $66.59 | 3 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $65.36 | 3 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $64.19 | 3 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $62.19 | 3 | 2025 |
Source payment records
|
|||||
| YONSA Normalized: yonsa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $61.87 | 3 | 2025 |
Source payment records
|
|||||
| XYNTHA Normalized: xyntha |
Biological | PBG PUERTO RICO LLC | $58.49 | 3 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $57.32 | 3 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $55.17 | 3 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $54.08 | 3 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $49.64 | 2 | 2025 |
Source payment records
|
|||||
| Xospata Normalized: xospata |
Drug | Astellas Pharma US Inc | $49.47 | 2 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | E.R. Squibb & Sons, L.L.C. | $48.16 | 3 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $47.17 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $47.17 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PBG PUERTO RICO LLC | $44.95 | 2 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PBG PUERTO RICO LLC | $44.95 | 2 | 2025 |
Source payment records
|
|||||
| BENEFIX Normalized: benefix |
Biological | PBG PUERTO RICO LLC | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PBG PUERTO RICO LLC | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Puerto Rico Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PBG PUERTO RICO LLC | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| ZIIHERA Normalized: ziihera |
Drug | JAZZ PHARMACEUTICALS INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PBG PUERTO RICO LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PBG PUERTO RICO LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PBG PUERTO RICO LLC | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| Columvi Normalized: columvi |
Biological | Genentech USA, Inc. | $12.22 | 1 | 2025 |
Source payment records
|
|||||
| Lunsumio Normalized: lunsumio |
Biological | Genentech USA, Inc. | $12.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 89 | exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYNPARZA lynparza |
2025 | Lynparza | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 9531 supporting records · 5030 recipient NPIs · example record 1206131376 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Eli Lilly Export S.A. Puerto Rico Branch Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 301 supporting records · 104 recipient NPIs · example record 1186465135 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 10903 supporting records · 6595 recipient NPIs · example record 1237992238 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 367 supporting records · 97 recipient NPIs · example record 1228798303 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
89 | 12 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 328 supporting records · 103 recipient NPIs · example record 1228797041 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
89 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 313 | 62 |
| Letrozole | Letrozole | 103 | 17 |
| Prednisone | Prednisone | 99 | 12 |
| Ibrance | Palbociclib | 89 | 12 |
| Exemestane | Exemestane | 62 | 13 |
| Hydroxyurea | Hydroxyurea | 51 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Revlimid | Lenalidomide | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Tagrisso | Osimertinib Mesylate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Lynparza | Olaparib | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Cyramza | Ramucirumab | 18 | suppressed |
| Gabapentin | Gabapentin | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | suppressed |
| Imbruvica | Ibrutinib | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 15 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 15 | suppressed |
| Famotidine | Famotidine/Pf | 15 | suppressed |
| Irinotecan Hcl | Irinotecan Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Arimidex | Anastrozole | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 13 | suppressed |
| Fluorouracil | Fluorouracil | 13 | suppressed |
| Fulphila | Pegfilgrastim-Jmdb | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 13 | suppressed |
| Sorafenib | Sorafenib Tosylate | 12 | suppressed |
| Verzenio | Abemaciclib | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 11 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
| Xtandi | Enzalutamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,017.45 · 262 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, AKEEGA, BENEFIX, BESREMI, BREYANZI, BRUKINSA, CABOMETYX, CALQUENCE, Columvi, DARZALEX, ELAHERE, ELIGARD, ELIQUIS, ELREXFIO, EMRELIS, ENHERTU, EPKINLY, ERLEADA, Fabhalta, Gavreto, HYMPAVZI, IBRANCE, IMBRUVICA, IMDELLTRA (AMG757), IMFINZI, INLYTA, INQOVI, Itovebi, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, KYPROLIS, LIBTAYO, LONSURF, LUMAKRAS, LUTATHERA, LYNOZYFIC, LYNPARZA, Lenvima, Lunsumio, MONJUVI, NERLYNX, NINLARO, Nubeqa, OGSIVEO, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Odomzo, Orserdu, PADCEV, PAXLOVID, PEMAZYRE, PLUVICTO, Polivy, RUBRACA, RYBREVANT, Rezlidhia, SARCLISA, SCEMBLIX, Stivarga, TAGRISSO, TALZENNA, TAVALISSE, Tecentriq, Trodelvy, VENCLEXTA, VERZENIO, VYNDAQEL, Vitrakvi, Vonjo, Vyloy, WELIREG, XGEVA, XT CDX, XTANDI, XYNTHA, Xospata, YONSA, ZEJULA, ZIIHERA, ZYNYZ | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ibrance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error